Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

Autor:	Hana Koutnikova, Salwa W. Rizkalla, Karine Clément, Milena Monteiro-Sepulveda, Jürgen Schrezenmeir, Bernd Genser, Jean-Michel Faurie
Přispěvatelé:	Danone Nutricia Research [Palaiseau, France], Centre Daniel Carasso [Palaiseau, France], BGStats Consulting [Vienna, Austria], Mannheimer Institut fur Public Health [Baden-Württemberg, Germany], Ruprecht Karls Universitat Heidelberg [Baden-Württemberg, Germany], Service de Nutrition [CHU Pitié-Salpétrière], Institut E3M [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Johannes Gutenberg - Universität Mainz (JGU), Clinical Research Center Kiel [Rheinland-Pfalz, Germany], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Danone Nutricia Research, Palaiseau, France. The work of BGStats Consulting was funded by Danone Research, Palaiseau, France. Danone Research supported collaborative work of the Institute of Cardiometabolism and Nutrition. JS received consultancy fee from Danone Research., Gestionnaire, Hal Sorbonne Université, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Nutrition et obésités: approches systémiques (UMR-S 1269) (Nutriomics), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de nutrition [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP]
Rok vydání:	2019
Předmět:	Alcoholic liver disease medicine.medical_specialty obesity bifidobacterium Gastroenterology 03 medical and health sciences 0302 clinical medicine Insulin resistance Diabetes mellitus Internal medicine medicine Diabetes Mellitus Humans 030212 general & internal medicine Bifidobacterium Randomized Controlled Trials as Topic 2. Zero hunger [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism Nutrition and Metabolism biology diabetes business.industry Probiotics Research Fatty liver non-alcoholic fatty liver disease General Medicine [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism medicine.disease biology.organism_classification Polycystic ovary Obesity 3. Good health lactobacillus [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition Treatment Outcome [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie Dietary Supplements [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie business Body mass index [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition 030217 neurology & neurosurgery
Zdroj:	BMJ Open BMJ Open, BMJ Publishing Group, 2019, 9 (3), pp.e017995. ⟨10.1136/bmjopen-2017-017995⟩ BMJ Open, 2019, 9 (3), pp.e017995. ⟨10.1136/bmjopen-2017-017995⟩
ISSN:	2044-6055
DOI:	10.1136/bmjopen-2017-017995⟩
Popis:	ObjectiveTo systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease.DesignSystematic review and meta-analysis.Data sourcesMedline, EMBASE and COCHRANE from 1990 to June 2018.Eligibility criteriaRandomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children ResultsOne hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=−0.94 kg mean difference, 95% CI −1.17 to −0.70, I²=0.0%), body mass index (k=32, d=−0.55 kg/m², 95% CI −0.86 to −0.23, I²=91.9%), waist circumference (k=13, d=−1.31 cm, 95% CI −1.79 to −0.83, I²=14.5%), body fat mass (k=11, d=−0.96 kg, 95% CI −1.21 to −0.71, I²=0.0%) and visceral adipose tissue mass (k=5, d=−6.30 cm², 95% CI −9.05 to −3.56, I²=0.0%). In type 2 diabetics, probiotics reduced fasting glucose (k=19, d=−0.66 mmol/L, 95% CI −1.00 to −0.31, I²=27.7%), glycated haemoglobin (k=13, d=−0.28 pp, 95% CI −0.46 to −0.11, I²=54.1%), insulin (k=13, d=−1.66 mU/L, 95% CI −2.70 to −0.61, I²=37.8%) and homeostatic model of insulin resistance (k=10, d=−1.05 pp, 95% CI −1.48 to −0.61, I²=18.2%). In subjects with fatty liver diseases, probiotics reduced alanine (k=12, d=−10.2 U/L, 95% CI −14.3 to −6.0, I²=93.50%) and aspartate aminotransferases (k=10, d=−9.9 U/L, 95% CI −14.1 to -5.8, I²=96.1%). These improvements were mostly observed with bifidobacteria (Bifidobacterium breve, B. longum), Streptococcus salivarius subsp. thermophilus and lactobacilli (Lactobacillus acidophilus, L. casei, L. delbrueckii) containing mixtures and influenced by trials conducted in one country.ConclusionsThe intake of probiotics resulted in minor but consistent improvements in several metabolic risk factors in subjects with metabolic diseases.Trial registration numberCRD42016033273.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc20a88f9c7271be0c8582cdd498fcc3 https://pubmed.ncbi.nlm.nih.gov/30928918 Zobrazit plný text záznamu